How a Nonprofit Had a $128K $1B Breakthrough
In this episode of The Tech Leaders Playbook, host Avetis Antaplyan sits down with Susan Ruediger, Founder and Chief Mission Officer of the CMT Research Foundation (CMTRF), and CEO Laura MacNeill. Together, they share how a nonprofit had a $128K $1B breakthrough — turning grassroots donations into a billion-dollar acquisition while inspiring a new model for patient-led research.
What Is CMT and Why Does It Matter?
Charcot-Marie-Tooth (CMT) disease is one of the most common inherited nerve disorders, though it remains unknown to many outside the medical community. CMT impacts the peripheral nervous system — the nerves that connect the brain and spinal cord to the rest of the body.
Symptoms typically begin with weakness, numbness, or difficulty moving toes and fingers. Over time, the disease can affect balance, mobility, hearing, and even breathing. It’s progressive, meaning it worsens over time, and because there are currently no FDA-approved treatments, patients have little to slow or reverse its course.
Globally, about 3 million people live with CMT, including 150,000 in the U.S. The biggest challenge in developing therapies is drug delivery. Getting medicine to the nerves in hands and feet without overwhelming the liver has historically been a roadblock — until recently. That’s where this nonprofit’s $128K–$1B breakthrough made history.
The $128K Bet That Sparked a $1B Deal
In 2019, CMTRF invested $128,000 in DTX Pharma, a small biotech with a promising way to deliver medicine directly to nerves. That seed investment created a ripple effect:
A $350K NIH grant to expand the research
A $100M private equity investment as results proved out
And ultimately, a $1B acquisition by Novartis
This was the turning point in how a nonprofit had a $128K $1B breakthrough. The deal validated CMT as a legitimate drug target, attracted global investor attention, and proved that rare-disease research can unlock blockbuster opportunities. Even more, it positioned CMT as a potential gateway to progress in ALS, Parkinson’s, and Alzheimer’s.
A Venture-Philanthropy Model Built for Impact
Unlike traditional nonprofits that spread resources across many programs, CMTRF is laser-focused: fund treatments, find a cure, and then close the foundation.
Their venture-philanthropy model works differently from standard grants:
Milestone-based funding: Money is tied to results, so ineffective projects don’t drag on.
Agility: Resources can pivot quickly if early data fails.
Reinvestment: Returns from successful exits go back into new projects, creating a cycle of progress.
As CEO Laura MacNeill explained: “We don’t want to exist forever. The goal is to go out of business by curing CMT.” That urgency is central to how a nonprofit had a $128K $1B breakthrough.
Lessons Leaders Can Take Away
The CMT Research Foundation’s journey offers lessons far beyond healthcare:
Small bets scale big. A modest $128K investment snowballed into $1B.
Focus is power. CMTRF says no to distractions and channels every dollar toward treatments.
Storytelling creates buy-in. Explaining the burden of CMT helped galvanize donors, biotech partners, and investors.
Partnerships unlock growth. Patient-led expertise paired with biotech innovation lowered risk and sped development.
At HIRECLOUT, we see the same truth in scaling teams. Companies grow fastest when they place the right people in the right roles — not when they try to do everything at once.
Get Involved
The CMT Research Foundation shows how a nonprofit had a $128K $1B breakthrough that reshaped both medicine and business. To learn more or contribute, visit cmtrf.org or connect with Susan Ruediger and Laura MacNeill on LinkedIn.
And if your company is scaling and needs the right talent to achieve its mission, visit HIRECLOUT.
